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1 18F-FDG = 2-deoxy-2-[18F]fluoro-D-glucose; PET = positron emission tomography; SUV = standardized uptake value.
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The excellent paper of Moadel and colleagues [1] gives
further support to the findings reported earlier by Meyer
and colleagues [2] suggesting that 18F-FDG may be of
benefit in treating hyper-metabolic neoplasms. For small
breast tumors in five mice injected with 18F-FDG
(2–4mCi, i.p.), Moadel and colleagues noted that 4% of
tumor cells stained for an apoptotic marker 10 days after-
ward versus less than 1% of controls. For larger tumors in
three older mice injected intra-peritoneally with 2mCi of
18F-FDG, necrosis was found to comprise about 14% of
the total tumor volume 10 days after the injection.
However, as shown in the first known autoradiographic
study of  deoxyglucose uptake in breast cancer [3] (see
Fig. 1), central necrotic areas could be identified which did
not accumulate tracer and comprised approximately 12.5%
of the estimated total tumor volume. As suggested by the
detail seen in figure one, autoradiography of tracer doses
of 18F-FDG in tissue sections would be an excellent way to
test a response to radiotherapeutic doses of this tumor
avid radiopharmaceutical, with the ability to simultaneously
perform histochemical staining of apoptosis markers.
In regards to the mean standardized uptake value (SUV) of
6.74 for the five breast tumors analyzed by the authors
using positron emission tomography (PET), this agrees
well with the mean SUV of 6.52 noted in a meta-analysis
of 159 breast cancer cases [4]. However, in regards to
the use of this data for dosimetry, the authors should con-
sider that positrons have a higher than expected relative
biologic effect, with S values that increase with smaller
tumor size [5].
More research is clearly needed on the potential use of
18F-FDG in treating breast cancer. In the same way that
PET imaging of tracer doses of 18F-FDG is very useful in
identifying occult breast cancer [6], it may prove to be of
benefit in a direct radiotherapeutic approach.
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Figure 1
Whole body coronal autoradiograph of 14C-deoxyglucose uptake
45 min after tail vein injection in a control mouse (A), compared to that
in a mouse with a transplanted breast adenocarcinoma (B). The
elevated deoxyglucose uptake within the tumor (B, rectangle), is
shown in more detail in the 12-fold enlargement seen in (C), which
displays a prominent lack of uptake within a central necrotic cavity.2
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